Helen & Robert Appel Alzheimer’s Disease Research Institute

Publications

Found 15 results
Author Title [ Type(Desc)] Year
Filters: Author is Holtzman, David M  [Clear All Filters]
Journal Article
Wong MYing, Lewis M, Doherty JJ, Shi Y, Cashikar AG, Amelianchik A, Tymchuk S, Sullivan PM, Qian M, Covey DF et al..  2020.  25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner.. J Neuroinflammation. 17(1):192.
Brendza RP, Bacskai BJ, Cirrito JR, Simmons KA, Skoch JM, Klunk WE, Mathis CA, Bales KR, Paul SM, Hyman BT et al..  2005.  Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice.. J Clin Invest. 115(2):428-33.
DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'dell MA, Taylor JW, Harmony JAK, Aronow BJ, Bales KR, Paul SM et al..  2004.  ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo.. Neuron. 41(2):193-202.
Shi Y, Yamada K, Liddelow SAntony, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC et al..  2017.  ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy.. Nature. 549(7673):523-527.
DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM.  2002.  Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.. Science. 295(5563):2264-7.
DeMattos RB, O'dell MA, Parsadanian M, Taylor JW, Harmony JAK, Bales KR, Paul SM, Aronow BJ, Holtzman DM.  2002.  Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease.. Proc Natl Acad Sci U S A. 99(16):10843-8.
Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM.  2005.  Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease.. J Biol Chem. 280(52):43236-42.
Hunter JM, Cirrito JR, Restivo JL, Kinley RD, Sullivan PM, Holtzman DM, Koger D, DeLong C, Lin S, Zhao L et al..  2012.  Emergence of a seizure phenotype in aged apolipoprotein epsilon 4 targeted replacement mice.. Brain Res. 1467:120-32.
Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, DeMattos RB, May PC et al..  2009.  A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.. Ann Neurol. 66(1):48-54.
Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM.  2002.  Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease.. Neurobiol Dis. 9(3):305-18.
Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C et al..  2011.  Human apoE isoforms differentially regulate brain amyloid-β peptide clearance.. Sci Transl Med. 3(89):89ra57.
Dodart J-C, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM et al..  2002.  Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.. Nat Neurosci. 5(5):452-7.
Zhao L, Gottesdiener AJ, Parmar M, Li M, Kaminsky SM, Chiuchiolo MJ, Sondhi D, Sullivan PM, Holtzman DM, Crystal RG et al..  2016.  Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models.. Neurobiol Aging. 44:159-72.
Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM.  2009.  Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance.. Neuron. 64(5):632-44.
Cirrito JR, Yamada KA, Finn MBeth, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM.  2005.  Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo.. Neuron. 48(6):913-22.